Abstract
We thank Drs. Whiteside and Trip for their comment on our editorial.1 The authors highlight noninfectious pneumonitis as a rare potential complication of alemtuzumab.2,3 The time course of onset in the 2 reported cases was different, with symptoms developing a few days or 1 month after infusion. Although not proven, this suggestion of immune-mediated mechanisms seem reasonable.2 This reaction may arise from antibody-dependent cell-mediated or complement-mediated cytolysis, which leads to cytokine release and then type III/IV hypersensitivity reaction and lung-resident T-cell activation. As for the side effects highlighted in our editorial,1 clinicians should recognize noninfectious pneumonitis as a potential rare complication of alemtuzumab, as it can respond well to corticosteroids.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
